Pasadena, CA-based Arrowhead Pharmaceuticals, which began as Mirus Corp. in Madison in 1995, announced a $267 million public stock offering, according to a corporate release.
The company sold 4.6 million shares of its common stock the week of Dec. 2–6, according to a Wisconsin State Journalstory, and most of the proceeds of the sale will go toward general funding and perhaps future acquisitions.
Arrowhead Pharmaceuticals is developing drugs that primarily target liver disease, using RNA interference, a technique that silences disease-causing genes.
